OUR NEWS - RECENT NEWS
Provincial Reference Tools: CATALIS Contributed to the Update
Provincial Reference Tools: CATALIS Contributed to the Update To fulfill its government mandate of optimizing Quebec’s clinical research environment and accelerating the development of innovative treatments for patients, CATALIS participated in the update of five provincial reference tools: the Standard Operating Procedures (SOPs) for Research Ethics Boards (REBs), the Statement on Optimizing the Research Contract Negotiation Process, a provincial
Catalis in Support of the Quebec Government’s Policy on Rare Diseases
CATALIS in Support of the Quebec Government’s Policy on Rare Diseases On June 6, the Quebec government unveiled its Politique québécoise pour les maladies rares (Quebec policy on rare diseases – in French only). In Quebec, 700,000 people with rare diseases, half of whom are children, face significant challenges such as errors in diagnosing their disease and the absence
MASter-1 Study: Authorization in 8 Weeks to Explore a New Treatment for an Extremely Rare Disease
MASter-1 Study: Authorization in 8 Weeks to Explore a New Treatment for an Extremely Rare Disease As mentioned in our December 2022 newsletter, CATALIS is proud to support the Quebec government’s Politique québécoise sur les maladies rares (Quebec policy on rare diseases – in French only), namely by allowing studies to be activated more quickly thanks to its FAST
STRENGTH Study: Zolgensma for Children Aged 2 to 12 With Spinal Muscular Atrophy
STRENGTH Study: Zolgensma for Children Aged 2 to 12 With Spinal Muscular Atrophy In October 2021, Minister Dubé announced that Zolgensma, a drug produced by the Novartis pharmaceutical company, was added to the list of drugs offered in Quebec health facilities to treat children under the age of 2 with spinal muscular atrophy. Spinal muscular atrophy is a rare
Astrazeneca and Vertex Join the Catalis Network
Astrazeneca and Vertex Join the Catalis Network CATALIS Quebec is very proud to announce that pharmaceutical companies AstraZeneca and Vertex are joining the CATALIS Network. As new members, they join Abbvie, Bayer, Boehriger Ingelheim, GSK, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda. Together, the partners support CATALIS in its mission to optimize the clinical research environment to accelerate the
NEPTUNUS-2 Study: Sjogren’s Syndrome Clinical Trial Approved in 8 Weeks via CATALIS’ FAST TRACK Evaluation Service
NEPTUNUS-2 Study: Sjogren’s Syndrome Clinical Trial Approved in 8 Weeks via CATALIS’ FAST TRACK Evaluation Service As mentioned in our December 2022 newsletter, CATALIS is proud to announce that its FAST TRACK Evaluation Service continues to allow industry-financed studies to be authorized in record time. In NEPTUNUS-2, a phase III study, Novartis and Dr. Isabelle Fortin are testing the
ONWARDS Study: Authorization in 9 Weeks for Symptomatic Osteoarthritis of the Knee Study via CATALIS’ FAST TRACK Evaluation Service
ONWARDS Study: Authorization in 9 Weeks for Symptomatic Osteoarthritis of the Knee Study via CATALIS’ FAST TRACK Evaluation Service In addition to the 3 rare disease studies, a 4th Novartis study on symptomatic osteoarthritis of the knee was authorized by the Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS) in record time via the CATALIS FAST TRACK
The Personalized Clinical Trial Support Service Assists Patients with Various Diseases, Including Rare Ones
The Personalized Clinical Trial Support Service Assists Patients with Various Diseases, Including Rare Ones CATALIS, under the banner Clinical Trials Quebec, is continuing the pilot implementation of its Personalized Clinical Trial Service. This province-wide, bilingual resource is free of charge; it is designed to help Quebec patients and their caregivers, regardless of their age or medical condition. This service
CATALIS’ Management Being Supported by Two New Advisory Committees
CATALIS’ Management Being Supported by Two New Advisory Committees Until recently, CATALIS’ management has been guided by three main advisory committees: a patient advisory committee made up of fifteen patient and patient-partner associations, a scientific and innovation advisory committee made up of expert clinical researchers, and an operations advisory committee made up of senior representatives from health institutions, pharmaceutical
Sanofi Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service
Sanofi Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service Following Novartis, Boehringer, and Roche, Sanofi is now CATALIS’ fourth pharmaceutical partner to pilot its FAST TRACK Evaluation Service. Sanofi’s Phase I-ll study, which uses human subjects for the first time and is designed to assess the safety and the pharmacokinetic, pharmacodynamic, and antitumor activity
Roche Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service
Roche Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service Thanks to CATALIS’ FAST TRACK evaluation service, Roche’s ProHer multi-centre study, which explores a new treatment method for patients with breast cancer, was approved in 10 weeks by the CHU de Québec-Université Laval. More specifically, this study seeks to discover patients’ preference for at-home administration
CATALIS Quebec Partners With N2 Canada for Provincial Contract Access to the CITI-Canada Training Platform
CATALIS Quebec Partners With N2 Canada for Provincial Contract Access to the CITI-Canada Training Platform CATALIS Quebec is very proud to partner with N2 Canada to provide its Network member healthcare institutions access to a shared training platform designed to ensure the conduct of high-quality research: the CITI-Canada training platform. Through this partnership, CATALIS Quebec officially becomes the new
Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service
Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service While the first-ever FAST TRACK evaluation service pilot project was successfully completed last December, CATALIS is proud to announce that two more clinical trials have now been approved in record time. The second FAST TRACK evaluation service coordinated a Phase I oncology study
Launch of New Shared Clinical Research Tools
Launch of New Shared Clinical Research Tools CATALIS and its network of public and private partners have facilitated the implementation of new shared tools designed to optimize the launching and conducting of clinical trials in Quebec; more specifically, CATALIS has coordinated the revision of documents serving to optimize the contract negotiation process with private industry and a memo which serves to
Danika Laberge Has Been Appointed President and Chief Executive Officer of CATALIS Quebec
Danika Laberge Has Been Appointed President and Chief Executive Officer of CATALIS Quebec CATALIS Quebec’s Board of Directors is pleased to announce the appointment of Danika Laberge as the organization’s President and Chief Executive Officer (CEO). “It is with tremendous enthusiasm and confidence in her abilities that the Board of Directors has appointed Ms. Laberge to the position of
Job Offer : Project Manager
We’re looking for a Project Manager who will help implement and conduct activities related to the FAST TRACK evaluation service for clinical trials in Québec. To view the job offer, click here.
CATALIS Quebec’s Network of Partners Now Includes 23 Quebec Health Institutions
CATALIS Quebec’s Network of Partners Now Includes 23 Quebec Health Institutions In keeping with its new government mandate of bringing together clinical research stakeholders, CATALIS Quebec is pleased to announce that it is expanding the scope of its activities to a larger number of institutions in the province: it has added 23 public institutions from Quebec’s health and social
Two New Administrators Join the CATALIS Board of Directors
Two New Administrators Join the CATALIS Board of Directors Dr. Guy A. Rouleau Dr. Guy Rouleau is Director of The Neuro (Montreal Neurological Institute-Hospital), Chair of the Department of Neurology and Neurosurgery of McGill University, Director of the Department of Neuroscience of McGill University Health Centre, and co-founder of the Tanenbaum Open Science Institute. He was recently elected Vice-President of
In recognition of Dr. Jacques Michaud and Dr. Michael Sebag for their work on the CATALIS Quebec Board of Directors
In recognition of Dr. Jacques Michaud and Dr. Michael Sebag for their work on the CATALIS Quebec Board of Directors After three years on the CATALIS Board of Directors, Dr. Jacques Michaud is now stepping down. On behalf of the CATALIS Board of Directors, I would like to acknowledge Dr. Michaud’s professionalism and dedication, and to thank him for
From Creating Operational and Structural Bases to Establishing New Services: CATALIS Québec Reached New Heights in 2021
From Creating Operational and Structural Bases to Establishing New Services: CATALIS Québec Reached New Heights in 2021 Now that 2021 has come to an end, I want to say how proud I am of CATALIS Québec’s achievements. I am impressed by our growing team’s accomplishments and the tremendous work its members did in a difficult context. We had to
A First Successful Pilot Project for CATALIS’ New FAST TRACK Evaluation Service: 4 Quebec Institutions Ranked in the Top 5 of the World’s Fastest Sites
A First Successful Pilot Project for CATALIS’ New FAST TRACK Evaluation Service: 4 Quebec Institutions Ranked in the Top 5 of the World’s Fastest Sites CATALIS is very proud to announce that the first pilot of its new FAST TRACK assessment service has successfully reduced the approval time for an industry-financed clinical trial by almost 75%. In September 2021,
CATALIS Is Piloting Its New FAST TRACK Evaluation Service
The CATALIS Public-Private Network has developed a new FAST TRACK evaluation service that will eventually allow industry-funded clinical trials to be authorized in less than 8 weeks.